BACKGROUND: Knowing the determinants of treatment satisfaction can provide better understanding of patient expectations in schizophrenia. The aim of this study was to determine which treatment-related factors were associated with treatment satisfaction, independently of patient-related or illness-related factors, in schizophrenia patients. METHODS: A cross-sectional study of data collected nationwide in France between 2005 and 2006 was conducted. 5500 adult patients with non-acute schizophrenia and requiring a switch of antipsychotic drug were included by 995 psychiatrists. Treatment satisfaction was assessed using the "PAtient SAtisfaction with Psychotropics" (PASAP) self-report questionnaire. Linear mixed model was used to explore the association between treatment satisfaction and treatment-related factors-including the current antipsychotic drug (none, first or second-generation antipsychotic) and psychosocial therapy-independently of patient-related and illness-related factors. FINDINGS: 3630 (66%) patients filled in the PASAP questionnaire. Main treatment-related determinants of higher levels of satisfaction were: (1) being on second-generation antipsychotics compared to first-generation antipsychotics (olanzapine: ß=1.2; CI95%=[0.5; 2.0], risperidone: ß=0.9; CI95%=[0.1; 1.6], clozapine: ß=2.5; CI95%=[0.6; 4.3] and amisulpride: ß=1.2; CI95%=[0.3; 2.1]) and (2) participating in psychosocial therapy (ß=0.9; CI95%=[0.3; 1.5]). CONCLUSION: Treatment satisfaction in non-acute schizophrenia was related to the more recent antipsychotic agents and psychosocial therapy, which may reflect expectations of more pro-active care.
BACKGROUND: Knowing the determinants of treatment satisfaction can provide better understanding of patient expectations in schizophrenia. The aim of this study was to determine which treatment-related factors were associated with treatment satisfaction, independently of patient-related or illness-related factors, in schizophreniapatients. METHODS: A cross-sectional study of data collected nationwide in France between 2005 and 2006 was conducted. 5500 adult patients with non-acute schizophrenia and requiring a switch of antipsychotic drug were included by 995 psychiatrists. Treatment satisfaction was assessed using the "PAtient SAtisfaction with Psychotropics" (PASAP) self-report questionnaire. Linear mixed model was used to explore the association between treatment satisfaction and treatment-related factors-including the current antipsychotic drug (none, first or second-generation antipsychotic) and psychosocial therapy-independently of patient-related and illness-related factors. FINDINGS: 3630 (66%) patients filled in the PASAP questionnaire. Main treatment-related determinants of higher levels of satisfaction were: (1) being on second-generation antipsychotics compared to first-generation antipsychotics (olanzapine: ß=1.2; CI95%=[0.5; 2.0], risperidone: ß=0.9; CI95%=[0.1; 1.6], clozapine: ß=2.5; CI95%=[0.6; 4.3] and amisulpride: ß=1.2; CI95%=[0.3; 2.1]) and (2) participating in psychosocial therapy (ß=0.9; CI95%=[0.3; 1.5]). CONCLUSION: Treatment satisfaction in non-acute schizophrenia was related to the more recent antipsychotic agents and psychosocial therapy, which may reflect expectations of more pro-active care.
Authors: Elizabeth A Klingaman; Deborah R Medoff; Stephanie G Park; Clayton H Brown; Lijuan Fang; Lisa B Dixon; Samantha M Hack; Stephanie L Tapscott; Mary Brighid Walsh; Julie A Kreyenbuhl Journal: Psychiatr Rehabil J Date: 2015-02-09
Authors: Gregory Kruse; Bruce J O Wong; Mei Sheng Duh; Patrick Lefebvre; Marie-Hélène Lafeuille; John M Fastenau Journal: Pharmacoeconomics Date: 2015-10 Impact factor: 4.981
Authors: Fu De Yang; Juan Li; Yun Long Tan; Wei Ye Liang; Rongzhen Zhang; Ning Wang; Wei Feng; Shangli Cai; Jian Min Zhuo; Li Li Zhang Journal: Neuropsychiatr Dis Treat Date: 2017-04-13 Impact factor: 2.570
Authors: Qinyu Chen; Eliza W Beal; Victor Okunrintemi; Emily Cerier; Anghela Paredes; Steven Sun; Griffin Olsen; Timothy M Pawlik Journal: J Patient Exp Date: 2018-08-27
Authors: Clementine Nordon; Constance Battin; Helene Verdoux; Josef Maria Haro; Mark Belger; Lucien Abenhaim; Tjeerd Pieter van Staa Journal: Clin Epidemiol Date: 2017-12-14 Impact factor: 4.790